Lang Matthew 4
4 · Lyell Immunopharma, Inc. · Filed Aug 11, 2023
Insider Transaction Report
Form 4
Lang Matthew
Chief Business Officer
Transactions
- Award
Option (right to buy)
2023-08-10+2,250,000→ 2,250,000 totalExercise: $2.31Exp: 2033-08-09→ Common Stock (2,250,000 underlying)
Footnotes (1)
- [F1]1/4 of the option shares shall vest on July 1, 2024, with the remaining option shares to vest in equal monthly installments over the following thirty-six months.